Page 3 of 36Oncopep�des AB Melfufen Powder for Solu�on for Infusion Module 1.11.3: Clinical Informa�on Amendment 3 1. Execu�ve summary The interpreta�on of the results of the melflufen study OP-103 is challenging due to the dissociated PFS and OS results with significantly heterogenic OS HRs across the age-spectrum. This dissocia�on between PFS and OS is caused by pomalidomide OS effect…
Long-term follow-up of multiple myeloma (MM) clinical trials are needed to assess long-term outcomes. We aimed to investigate the length of follow-up of all phase…
Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic precursor condition that precedes multiple myeloma and related disorders but has also been associated with other…
Introduction Multiple myeloma (MM) is a malignancy of bone marrow plasma cells, characterized by monoclonal immunoglobulins in the blood or urine and assoc
Blood Cancer Journal – Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response
As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by…
Background: Lenalidomide/dexamethasone has been approved as a standard treatment in multiple myeloma and is applied preferentially in older patients with c
8012 Background: Early and sensitive detection of bone marrow disease and stratified patient management according to clinical risk can confer survival advantages in multiple myeloma…
Myeloma cast nephropathy (MCN) is a common cause of severe renal impairment in multiple myeloma (MM). The level of free light chain (FLC) that causes…
Multiple myeloma (MM) patients frequently attain a bone marrow (BM) minimal residual disease (MRD) negativity status in response to treatment. We identified 568 patients who…
Almost all patients with multiple myeloma (MM) eventually relapse, either asymptomatically or with end-organ damage. However, it remains unclear whether initiating therapy at the time…
